[Thoughts on the neurobiological aspects of Parkinson syndrome].
The Parkinson-syndrome is the most important syndrome under the extrapyramidal disease. The therapy with L-DOPA has a prominent place in the therapy of Parkinson disease since the introduction of oral effective drugs. Dopamin has an effect to the basalganglia as a neurotransmitter and perhaps an inhibition effect to specific synapses of brain. The inhibition or the optimal balance of the cholinergic systems is the effect of Dopamin and Noradrenalin. The therapy with low dosis of L-DOPA in combination with a decarboxylase-inhibitor will be prevent the side-effects of nerv-cells.
D001479:Basal Ganglia / Q000503:physiopathology; D004298:Dopamine / Q000502:physiology*; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D009638:Norepinephrine / Q000502:physiology; D010300:Parkinson Disease / Q000188:drug therapy / Q000503:physiopathology*; D011954:Receptors, Dopamine / Q000187:drug effects; D013569:Synapses / Q000502:physiology; D009435:Synaptic Transmission / Q000187:drug effects
D011954:Receptors, Dopamine; D007980:Levodopa; D004298:Dopamine; D009638:Norepinephrine
Einige Gedanken zu neurobiologischen Aspekten beim Parkinsonsyndrom.